Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.29B P/E - EPS this Y 2.70% Ern Qtrly Grth -
Income -149.65M Forward P/E -6.04 EPS next Y -14.00% 50D Avg Chg 3.00%
Sales 38.34M PEG - EPS past 5Y - 200D Avg Chg 31.00%
Dividend N/A Price/Book 5.50 EPS next 5Y - 52W High Chg -16.00%
Recommedations 1.40 Quick Ratio 5.07 Shares Outstanding 58.69M 52W Low Chg 115.00%
Insider Own 7.47% ROA -24.89% Shares Float 45.82M Beta 1.10
Inst Own 91.67% ROE -52.79% Shares Shorted/Prior 3.48M/3.29M Price 25.84
Gross Margin -276.60% Profit Margin - Avg. Volume 294,327 Target Price 61.53
Oper. Margin -593.35% Earnings Date Aug 5 Volume 167,277 Change -1.67%
About Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V. News
06:00 AM Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
05/27/24 Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
05/24/24 Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
05/24/24 Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
05/24/24 Merus Clears Wall Street's Bar With Cancer Data
05/24/24 Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities
05/24/24 Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
05/24/24 ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
05/23/24 Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
05/23/24 Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
05/13/24 Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
05/11/24 Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
05/10/24 Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame
05/08/24 Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
05/06/24 Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
04/29/24 Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
04/26/24 Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
04/25/24 Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
04/24/24 Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
04/08/24 Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
MRUS Chatroom

User Image GPS_OS_21_vs_SOC_5 Posted - 1 hour ago

$SLS While we wait for the GPs Phase 3 Results -- take a look at this 60% ORR 10 patient p2 Cohort added more than a billion to the $MRUS market cap Friday

User Image ApexSeidon Posted - 4 hours ago

$MRUS 65C STO 7/19exp $628k 5.43 Avg

User Image DonCorleone77 Posted - 6 hours ago

$MRUS Merus announces interim clinical data on petosemtamab with pembrolizumab Merus announced interim clinical data as of a March 6, 2024 data cutoff from the ongoing phase 1/2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Jerome Fayette M.D. Ph.D., Centre Leon Berard, Lyon, France at the 2024 American Society of Clinical Oncology Annual Meeting on Monday, June 3 at 8 a.m. CT. Petosemtamab: Solid Tumors: Rapid oral presentation title: Petosemtamab with pembrolizumab as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma: Phase 2 study. Observations in the presentation include: As of a March 6, 2024 data cutoff date, 45 patients were treated; 26 patients were enrolled as of the abstract cutoff date; The efficacy population consisted of 24 patients who had the opportunity for 4 or more months follow up, with greater than or equal to2 treatment cycles and greater than or equal to1 post-baselinetumor assessment; or whodiscontinued early due to diseaseprogression or death; Two patients were not included: One patient withdrew consent prior to first tumor assessment and the other patient discontinued due to toxicity with less than 2 cycles of treatment; Response rates overall: 67%, including 1 confirmed complete response, 12 confirmed partial responses and 3 unconfirmed PRs by Response Evaluation Criteria in Solid Tumors v1.1. per investigator assessment, including; 3 of 4 patients with HPV associated cancer responded; Responses observed across PD-L1 levels; At the time of data cutoff, 32 patients of the 45 enrolled, remained on treatment, including 14 of 16 responders and 18 of the initial 26 patients enrolled; Median follow up of 3.6 months for the 45 patients; In 45 patients the combination was well tolerated and no significant overlapping toxicities with pembrolizumab were observed; Treatment-emergent adverse events were reported in 45 pts; Most were Grade 1 or 2 in severity; Infusion-related reactions were reported in 38% and 7% of pts, most occurred during the first infusion and resolved.

User Image Stock_Titan Posted - 6 hours ago

$MRUS Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC https://www.stocktitan.net/news/MRUS/merus-petosemtamab-in-combination-with-pembrolizumab-interim-data-cqhccn091a7p.html

User Image DonCorleone77 Posted - 16 hours ago

$MRUS Attached is page 1 from a report issued by WC Wainwright on 5/24/24 that gave MRUS a Buy rating and a $65 price target. The 'Valuation and Risks' section in the report stated the following: Our price target of $63.4/share is based on an equally weighted composite of: (a) $67.20/share, as a 25x multiple of taxed and diluted FY34 EPS of $8.35, discounted back to FY24 at 12.0%; and (b) an NPV of $63.4/share (discounted cash flow analysis using a 12.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Risks to achieving our price target include regulatory, commercial, clinical development, manufacturing, financial, liability and intellectual property risks.

User Image TheDizPlinTrader Posted - 17 hours ago

$MRUS Daily Analysis: 1-Hour Support & Resistance Zones 🚀 Current Price: $60.47 🔹 Support Levels: Immediate support at $59.50 Stronger support at $58.00 🔸 Resistance Levels: Immediate resistance at $61.50 Longer-term resistance at $63.00 News: Thursday, Merus N.V. announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting website. 📊 Watch these key levels for potential trading opportunities! Stay disciplined! ⚔️ 🔍 Want more insights? Visit my profile for a link to my website!

User Image FlynancialAnalyst Posted - 21 hours ago

$MRUS Can't catch em all, wow

User Image MikeCaymanTrades Posted - 23 hours ago

$MRUS strong move on on friday. 37%

User Image JonhanDAO Posted - 1 day ago

There are 39 trades today Stock: $MRUS Current Price: 59.9900016784668 Open: 52.599998474121094 High: 61.61000061035156 Low: 52.34000015258789 Volume: 6907200 Activity: Neutral Entry Price: Private Exit Price: Private Expiry Date: Private Data provided by: https://bit.ly/3V4wZ9k

User Image dixiebull Posted - 1 day ago

$MINM not much volume took it to 4.62, see if 4.15 holds for a move to 5 $DELL made to it all targets, getting to 166.77, leveling out at vwap. Break of 162 can take it back to 163 and 165 $DECK beauty of a play from earnings in the low 900's to test 1037. Vwap is around 1022 so we will see if that can hold for a possible new high $CRDO slow grind to break 20, if it can keep that level with volume it can get 22 $MRUS I talked about before it ran Friday from 50.55 to 61.61, see if 60 can hold for a move to 62.50 and 63 to 65

User Image Alejos11 Posted - 1 day ago

$MRUS

User Image signaljumper Posted - 2 days ago

$MRUS breakout on new 52 week highs support red resistance green #chartcheck #signaljumper follow me, chartings, DDs and alerts

User Image Fullratio Posted - 2 days ago

$MRUS debt is 97% smaller than its equity: https://fullratio.com/stocks/nasdaq-mrus/merus

User Image Rome777 Posted - 3 days ago

$MRUS https://www.defenseworld.net/2024/05/25/swiss-national-bank-has-2-million-holdings-in-merus-nasdaqmrus.html

User Image dixiebull Posted - 3 days ago

$MINM not much volume took it to 4.62, see if 4.15 holds for a move to 5 $DELL made to it all targets, getting to 166.77, leveling out at vwap. Break of 162 can take it back to 163 and 165 $DECK beauty of a play from earnings in the low 900's to test 1037. Vwap is around 1022 so we will see if that can hold for a possible new high $CRDO slow grind to break 20, if it can keep that level with volume it can get 22 $MRUS I talked about before it ran Friday from 50.55 to 61.61, see if 60 can hold for a move to 62.50 and 63 to 65

User Image cholle Posted - 3 days ago

$MRUS +34.99%

User Image tradingtwenty Posted - 3 days ago

Top 5 stock gainers today that have trended in the past 24 hours: $LUCY 428.49% 🔥 $AKAN 71.97% $ONMD 56.46% $TKLF 38.89% $MRUS 36.12% Link: https://tradingtwenty.com/dashboard/trending/past

User Image Stocksrunner Posted - 3 days ago

Friday Top Gainers $MRUS - up on strong oncology study results and positive analyst updates. $ASTS - rises despite ongoing litigation, driven by investor interest. $DECK - gains after Q4 earnings beat and raised price target by Citi. $GH - jumps following FDA panel support for its blood-based colon cancer test. $MGNI - increases after BofA upgrades stock to buy.

User Image bostondaytrader Posted - 3 days ago

$ONON - 52-week High, HUGE volume, and we're about to SQUEEZE into the close. Let's go! Other plays: $ONMD $MINM $MRUS $OKLO

User Image Stocksrunner Posted - 3 days ago

Friday High Volume Alerts $MRUS - Surges on positive oncology study results. $GNLX - Spikes after $27.5M stock offering announcement. $ATAT - Gains attention with new ESG report. $WDAY - High volume post-earnings, despite revised guidance.

User Image stocklooter Posted - 3 days ago

$mrus up 35%. it has melonoma drug.

User Image ShortingTheTrend Posted - 3 days ago

$MRUS $MRNA $IMCR $GILD The biggest weekend in cancer science is just a week away, which means that the research analysts who cover biopharma for Wall Street banks got very little sleep on Thursday night. The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting, which runs through June 4 and draws not only research scientists and clinicians from around the world, but also a parade of biopharma companies, and the investors who track them. Late Thursday, ASCO released most of the 5,000 summaries of research to be presented at the conference, including trial results from lots and lots of pharma and biotech names

User Image Run2Runn2Runnn Posted - 4 days ago

$IOVA $MRUS Thanks 🙏 everyone. Happy Memorial Day!!! Let’s saturate our shoulders!!

User Image Run2Runn2Runnn Posted - 4 days ago

$IOVA $MRUS made my day!!!

User Image Capitulation_0 Posted - 4 days ago

$XBI ASCO24 one the biggest conferences.. so how many winners did it yield? yeah.. not many. $MRUS, $ELEV, $AGEN, $CGEM? No BO. No fanfare, None of the major financial news outlet is talking about it. XBI barely green. Great sector!

User Image lamberjack Posted - 4 days ago

$MRUS

User Image Capitulation_0 Posted - 4 days ago

$MRUS The question is: How long before they get paid? Lawsuits can be extended for years through appeals. Time to settle. $REGN was smart.. the settled.

User Image tradingtwenty Posted - 4 days ago

Top midday stock gainers: $LUCY $ONMD $AKAN $NCPL $MRUS 🔥 Link: https://tradingtwenty.com/dashboard/trending/past

User Image Sciautomat Posted - 4 days ago

$MRUS +36% because of the results observed among 10 patients!!!

User Image tradethehalt Posted - 4 days ago

Mid-Day Top 5 Gainers Report: $LUCY (231%) $AKAN (62%) $ONMD (48%) $TKLF (40%) $MRUS (37%) If we missed a split/reverse split, let us know!

Analyst Ratings
B of A Securities Buy May 24, 24
HC Wainwright& Co. Buy May 24, 24
Needham Buy May 24, 24
Needham Buy May 13, 24
HC Wainwright & Co. Buy May 9, 24
Needham Buy Apr 11, 24
Truist Securities Buy Mar 28, 24
Needham Buy Mar 7, 24
Needham Buy Mar 4, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Silverman Peter B. COO & GC COO & GC Dec 15 Sell 25 22,386 559,650 12/18/23
Iwicki Mark T Director Director Apr 14 Option 7.27 73,576 534,898 73,576 04/17/23
Liu Hui EVP, CBO & Head of M.. EVP, CBO & Head of Merus US Apr 06 Option 7.86 98,085 770,948 156,016 04/10/23
Shuman Harry VP Controller, PAO VP Controller, PAO Aug 25 Sell 24.33 165 4,014 1,760 08/29/22
Lundberg Sven Ante President, CEO & PFO President, CEO & PFO Aug 19 Buy 22.9928 704 16,187 20,044 08/22/22
Lundberg Sven Ante President, CEO & PFO President, CEO & PFO Jul 12 Buy 22.9688 4,340 99,685 19,340 07/13/22
Silverman Peter B. EVP, GC and Head of.. EVP, GC and Head of Utrecht Mar 10 Option 11.16 60,000 669,600 60,000 03/11/22
Silverman Peter B. EVP, GC and Head of.. EVP, GC and Head of Utrecht Mar 10 Sell 26.95 60,000 1,617,000 03/11/22
BVF PARTNERS L P/IL 10% Owner 10% Owner Oct 07 Sell 27.66 1,132,714 31,330,869 232,747 10/08/21